AZD0865
Modify Date: 2024-01-04 15:55:55
AZD0865 structure
|
Common Name | AZD0865 | ||
|---|---|---|---|---|
| CAS Number | 248919-64-4 | Molecular Weight | 366.45700 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H26N4O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AZD0865AZD0865 inhibits gastric H+,K+-ATPase by K+-competitive binding. (IC50: 1.0 ± 0.2 μM)It is a acid-suppressing agents with rapid onset of action and potent acid inhibition. In vitro: AZD0865 can inhibit the final step in acid secretion. AZD0865 reduced porcine renal Na+,K+-ATPase activity by 9 ± 2%, demonstrating a high selectivity for H+,K+-ATPase.In vivo: The reference for animal administration is 0.5-1.0 mg/kg. The greater degree of acid suppression with the 75-mg dose of AZD0865 would translate to a healing rate of 89% at 4 weeks. |
| Name | 8-[(2,6-dimethylphenyl)methylamino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide |
|---|---|
| Synonym | More Synonyms |
| Description | AZD0865 inhibits gastric H+,K+-ATPase by K+-competitive binding. (IC50: 1.0 ± 0.2 μM)It is a acid-suppressing agents with rapid onset of action and potent acid inhibition. In vitro: AZD0865 can inhibit the final step in acid secretion. AZD0865 reduced porcine renal Na+,K+-ATPase activity by 9 ± 2%, demonstrating a high selectivity for H+,K+-ATPase.In vivo: The reference for animal administration is 0.5-1.0 mg/kg. The greater degree of acid suppression with the 75-mg dose of AZD0865 would translate to a healing rate of 89% at 4 weeks. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C21H26N4O2 |
|---|---|
| Molecular Weight | 366.45700 |
| Exact Mass | 366.20600 |
| PSA | 82.15000 |
| LogP | 3.54990 |
| Linaprazan [INN:BAN] |
| UNII-E0OU4SC8DP |
| AZD0865 |
| Linaprazan |